Search Results
May 05, 2026, 09:46 ET GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
May 05, 2026, 09:00 ET GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit - Contact The Gross Law Firm
May 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: The Gross Law Firm
May 01, 2026, 10:03 ET GOSS SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 30, 2026, 19:58 ET GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as
More news about: THE ROSEN LAW FIRM, P. A.
Apr 30, 2026, 19:42 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 30, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Patient Enrollment Quality: SueWallSt
hundreds of millions of dollars for investors.Frequently Asked Questions About the GOSS LawsuitQ: Who is eligible to join the GOSS investor lawsuit? A: Investors who purchased GOSS stock or securities between June 16, 2025 and February 20, 2026 and suffered financial losses
More news about: SueWallSt.com
Apr 30, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 29, 2026, 15:00 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS).
More news about: Glancy Prongay Wolke & Rotter LLP
Apr 29, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: Levi & Korsinsky
29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: Levi & Korsinsky
Apr 28, 2026, 12:00 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JUNE 1, 2026 (LEAD PLAINTIFF DEADLINE)
More news about: Law Offices of Howard G. Smith
Apr 28, 2026, 09:00 ET Lost Money on Gossamer Bio, Inc. (GOSS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: The Gross Law Firm
Apr 27, 2026, 21:32 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 24, 2026, 16:30 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 23, 2026, 18:56 ET INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 23, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: SueWallSt
among ISS Top 50 for seven consecutive years.Frequently Asked Questions About the GOSS LawsuitQ: Who is eligible to join the GOSS investor lawsuit? A: Investors who purchased GOSS stock or securities between June 16, 2025 and February 20, 2026 and suffered financial losses
More news about: SueWallSt.com
Apr 23, 2026, 02:34 ET DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS
[3] Ngoi NYL, Choi CH, Zhu J, Lim D, Tan TZ, Sun H, Heong V, Ow SGW, Chay WY, Kim HS, Lim YW, Lim SE, Goss G, Goh JC, Kim JW, Friedlander M, Tai BC, Kim K, Tan DSP. Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma
More news about: National University Cancer Institute, Singapore (NCIS)
Apr 22, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky
seven consecutive years.Frequently Asked Questions About the GOSS LawsuitQ: What is the GOSS class action lawsuit about? A: A securities class action has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) alleging materially false and misleading statements between June 16,
More news about: Levi & Korsinsky, LLP
Apr 22, 2026, 08:24 ET GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 21, 2026, 17:55 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action - Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 21, 2026, 09:00 ET GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit -- The Gross Law Firm
April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: The Gross Law Firm
Apr 17, 2026, 08:21 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-gossamer-bio-inc-of-class-action-lawsuit-and-upcoming-deadlines--goss-302744221.htmlSOURCE
More news about: Pomerantz LLP
Apr 16, 2026, 09:48 ET GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 16, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing to Disclose Trial Risks: SueWallSt
www.zlk.comFrequently Asked Questions About the GOSS LawsuitQ: What is the GOSS lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is June 1, 2026. This deadline applies only
More news about: SueWallSt.com
Apr 15, 2026, 21:12 ET Robbins LLP Encourages GOSS Stockholders Who Lost Money Investing in Gossamer Bio, Inc. to Contact the Firm for Information About Leading the Class Action
LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization
More news about: Robbins LLP